Nasdaq

Vigil Neuroscience Advances VG-3927 into Phase 2 Trial as a Promising Once-Daily Oral Therapy for Alzheimer's Disease Following Positive Phase 1 Results

Demonstrated a favorable safety and tolerability profile for VG-3927 across all cohorts, including elderly participants, with no serious adverse events reported. Achieved robust and dose-dependent ...
Nasdaq

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease

WATERTOWN, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...
Seeking Alpha

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

- First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease (AD) - “We are thrilled to showcase our preclinical and Phase 1 ...
manilatimes

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

- First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer's disease (AD) - WATERTOWN, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Vigil ...
Business Insider

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease

- Safety, tolerability, pharmacokinetic and pharmacodynamic profile of VG-3927 supports continued development as potential once-daily oral therapy for Alzheimer’s disease (AD) - - VG-3927 achieved ...
Seeking Alpha

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease

- New preclinical and clinical data from SAD cohorts to be presented at upcoming 2024 Alzheimer’s Association International Conference (AAIC) - - Company plans to report complete Phase 1 data, ...